QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Forecast, Price & News

$1.08
-0.03 (-2.70%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.05
$1.12
50-Day Range
$0.81
$1.13
52-Week Range
$0.77
$2.42
Volume
121,355 shs
Average Volume
230,871 shs
Market Capitalization
$56.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.17

Assembly Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
100.6% Upside
$2.17 Price Target
Short Interest
Healthy
0.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
0.09mentions of Assembly Biosciences in the last 14 days
Based on 35 Articles This Week
Insider Trading
Selling Shares
$55,227 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

109th out of 987 stocks

Pharmaceutical Preparations Industry

47th out of 478 stocks


ASMB stock logo

About Assembly Biosciences (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ASMB Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
See More Headlines

ASMB Price History

ASMB Company Calendar

Last Earnings
3/22/2023
Today
6/09/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ASMB
CUSIP
92282210
Employees
102
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$2.17
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+95.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-93,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.25 million
Book Value
$1.69 per share

Miscellaneous

Free Float
49,828,000
Market Cap
$57.85 million
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Jason A. Okazaki
    President, Chief Executive Officer & Director
  • William DelaneyWilliam Delaney
    Chief Scientific Officer
  • John O. Gunderson
    Secretary, Vice President & General Counsel
  • Michele Anderson
    Chief Development Officer
  • Nicole S. White
    Chief Manufacturing Officer













ASMB Stock - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings
or view top-rated stocks.

What is Assembly Biosciences' stock price forecast for 2023?

3 brokers have issued 1 year price targets for Assembly Biosciences' stock. Their ASMB share price forecasts range from $1.50 to $3.00. On average, they expect the company's stock price to reach $2.17 in the next year. This suggests a possible upside of 95.2% from the stock's current price.
View analysts price targets for ASMB
or view top-rated stocks among Wall Street analysts.

How have ASMB shares performed in 2023?

Assembly Biosciences' stock was trading at $1.30 at the start of the year. Since then, ASMB shares have decreased by 14.6% and is now trading at $1.11.
View the best growth stocks for 2023 here
.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a drop in short interest in May. As of May 15th, there was short interest totaling 161,300 shares, a drop of 5.5% from the April 30th total of 170,600 shares. Based on an average daily volume of 214,900 shares, the short-interest ratio is presently 0.8 days.
View Assembly Biosciences' Short Interest
.

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ASMB earnings forecast
.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its quarterly earnings data on Wednesday, March, 22nd. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.10.

What ETF holds Assembly Biosciences' stock ?

ETFMG Treatments Testing and Advancements ETF holds 16,315 shares of ASMB stock, representing 0.07% of its portfolio.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?
What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.08%), Hudson Bay Capital Management LP (1.82%), Platinum Investment Management Ltd. (1.71%), Renaissance Technologies LLC (1.47%), Federated Hermes Inc. (0.70%) and Dimensional Fund Advisors LP (0.55%). Insiders that own company stock include Jacqueline Sybil Papkoff, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends
.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $1.11.

How much money does Assembly Biosciences make?

Assembly Biosciences (NASDAQ:ASMB) has a market capitalization of $57.85 million and generates $6.25 million in revenue each year. The biopharmaceutical company earns $-93,090,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

How many employees does Assembly Biosciences have?

The company employs 102 workers across the globe.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.assemblybio.com. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at lglaser@assemblybio.com, or via fax at 646-706-5101.

This page (NASDAQ:ASMB) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -